Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Abstract

Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain termination is RDV's plausible mechanism of action. Here, we expressed and purified active SARS-CoV-2 RdRp composed of the nonstructural proteins nsp8 and nsp12. Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA. Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i +3. We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps. A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP. In this regard, the triphosphate forms of 2′-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits. Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not observed. These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral.

Cited by papers we hold 22

• Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms · 2022
  No notice
• 4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication · 2022
  No notice
• Potential Nanospray Inhalation of Remdesivir and Hydroxychloroquine using Poly (lactic-co-glycolic) Acid as Fast Delivery for Covid-19 Treatment. · 2021
  Not checked
• The Therapeutic Effect of Traditional Chinese Medicine on Inflammatory Diseases Caused by Virus, Especially on Those Caused by COVID-19 · 2021
  Not checked
• Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review · 2021
  Not checked
• Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants · 2021
  No notice
• A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication · 2021
  No notice
• COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies · 2021
  No notice
• Mechanism of SARS-CoV-2 polymerase stalling by remdesivir · 2021
  No notice
• In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2 · 2021
  No notice
• Broad-Spectrum Antiviral Strategies and Nucleoside Analogues · 2021
  No notice
• SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication · 2021
  No notice
• Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies · 2021
  No notice
• Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis · 2021
  No notice
• A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL pro Inhibitor PF-00835231 as a Potential New Treatment for COVID-19 · 2021
  No notice
• Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay · 2021
  No notice
• Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir · 2020
  No notice
• Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 · 2020
  Not checked
• Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication · 2020
  Corrected
• The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19 · 2020
  No notice

and 2 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.